R. Officinalis as Pulpotomy Agent in Permanent Teeth With Irreversible Pulpitis
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-40
SponsorUniversity of Health Sciences Lahore
About this trial
This study evaluates and compares the clinical and radiographic outcomes of Rosmarinus officinalis and Mineral Trioxide Aggregate (MTA) when used as pulpotomy medicaments in vital mature permanent teeth with irreversible pulpitis. The aim is to determine the effectiveness of both materials in terms of pain reduction and periapical healing. While MTA is considered a gold standard, it has limitations such as high cost, long setting time, and potential discoloration. Therefore, this study investigates Rosmarinus officinalis as a natural, cost-effective alternative with comparable therapeutic potential. This study also provide an alternative to RCT in teeth with irreversible pulpitis
Eligibility criteria
Qualifiers
Healthy patients (ASA classification 1 and 2) of age range of 18-40 of both sexes would be included.
Vital mature permanent posterior teeth with deep caries approaching the pulp as seen on periapical x-ray.
Pain indicative of irreversible pulpitis (spontaneous pain or pain exacerbated by a cold stimulus which could last from a few seconds to hours), which a cold test could reproduce.
Tooth will be selected on the basis of working diagnosis i.e. successful hemostasis within 5 minutes after removal of coronal pulp.
Disqualifiers
Patients with ASA classification 3, 4 ,5 and 6 would be
Patients taking antibiotics within last 2 weeks.
Teeth with pulp necrosis, cracked tooth, internal or external resorption, calcified canals, acute or chronic apical periodontitis with an associated sinus tract or periapical radiolucency.
Periodontally compromised tooth.
Trial design
Treatments tested in this trial
- MTA Pulpotomy
- Rosemarinus officinalis extract pulpotomy
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Health Sciences Lahore
Lead sponsor
Postgraduate Medical Institute, Lahore
Sponsor institution
Source ClinicalTrials.gov